Wuhan Hiteck Biological Pharma Co.,Ltd

300683

CNE1000034C5

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-04-18 pm EDT			5-day change	1st Jan Change
21.77 ^CNY	-1.49%		-12.18%	-39.71%

2023	Wuhan Hiteck Biological Pharma Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023	CI
2023	Hiteck Biological Pharma Gets Nod to Trial Eye Drops	MT

Wuhan Hiteck Biological Pharma Co.,Ltd Approves the Cash Dividend for the Year 2019

May 21, 2020 at 03:38 pm EDT

Wuhan Hiteck Biological Pharma Co.,Ltd at the AGM held on May 20, 2020, approved the cash dividend/10 shares (tax included): CNY 1.60000000 for the year 2019.

Latest news about Wuhan Hiteck Biological Pharma Co.,Ltd

Wuhan Hiteck Biological Pharma Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-24	CI
Hiteck Biological Pharma Gets Nod to Trial Eye Drops	23-10-09	MT
Wuhan Hiteck Biological Pharma Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-30	CI
Wuhan Hiteck Biological Pharma Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-24	CI
Wuhan Hiteck Biological Pharma Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-24	CI
Wuhan Hiteck Biological Pharma Co.,Ltd announced that it has received CNY 294.999985 million in funding from Nuode Asset Management Co., Ltd., Caitong Fund Management Co., Ltd., Shanghai Boshen Investment Center (Limited Partnership), Shenzhen Qianhai Eagle Fund Management Co., Ltd., UBS Group AG, Guodu Venture Capital Co., Ltd., and other investors	23-02-01	CI
Hiteck Biological Pharma Gets Regulatory Consent for Share Sale	23-01-23	MT
Wuhan Hiteck Biological Pharma Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-24	CI
Wuhan Hiteck Biological Pharma Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-02	CI
Wuhan Hiteck Biological Pharma Co.,Ltd announced that it expects to receive CNY 300 million in funding	22-05-17	CI
Wuhan Hiteck Biological Pharma Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-22	CI
Wuhan Hiteck Biological Pharma Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-22	CI
Wuhan Hiteck Biological Pharma Co.,Ltd Approves Board Appointments	21-12-13	CI
Wuhan Hiteck Biological Pharma Co.,Ltd agreed to acquire additional 6.9416% stake in Beijing Shadong Biotechnology Co., Ltd. from Beijing Zhongguancun VC Development Co., Ltd.	21-11-14	CI
Wuhan Hiteck Biological Pharma Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	21-10-28	CI
Wuhan Hiteck Biological Pharma : Bio-Pharma Nets $91 Million From Private Placement	21-10-14	MT
Wuhan Hiteck Biological Pharma Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021	21-08-25	CI
Wuhan Hiteck Biological Pharma Co., Ltd. announced that it has received CNY 599.972 million in funding from a group of investors	21-08-03	CI
Xiweiai Pharmaceutical Technology Co., Ltd. announced that it expects to receive CNY 30 million in funding from Wuhan Hiteck Biological Pharma Co.,Ltd	21-07-20	CI
Wuhan Hiteck Biological Pharma Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-04-22	CI
Wuhan Hiteck Biological Pharma Co., Ltd. Announces Executive Changes	21-01-25	CI
Wuhan Hiteck Biological Pharma Co.,Ltd intends to acquire a 67% stake in Xiamen Weijia Pharmaceutical Co., Ltd. from Yongxin County Xinxinyuan Enterprise Management Consulting Center (Limited Partnership) for CNY 70.01 million.	20-11-12	CI
Wuhan Hiteck Biological Pharma Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2020	20-10-26	CI
Wuhan Hiteck Biological Pharma Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2020	20-08-28	CI
Wuhan Hiteck Biological Pharma Co., Ltd. announced that it expects to receive CNY 975.227 million in funding from a group of investors	20-07-13	CI

Chart Wuhan Hiteck Biological Pharma Co.,Ltd

Duration

Period

Chart Wuhan Hiteck Biological Pharma Co.,Ltd

More charts

Wuhan Hiteck Biological Pharma Co Ltd is a biopharmaceutical company. The Company operates five segments. The Biopharmaceutical segment is engaged in research, development, production and sales of biological products, and its primary product is mouse nerve growth factor for injection named Jinlujie. The Medical Technology Service segment is mainly involved in the technical development, technical consultation and technology transfer of chemical drugs. The In Vitro Diagnostic Reagents segment operates the research, development, production and sales of in vitro diagnostic reagents. The Pharmaceutical Sales and Wholesale segment is engaged in the sales and wholesale of pharmaceuticals. The Other segmentâs businesses include the cultivation and sales of Chinese herbal medicines, and the wholesale and retail of health products.

Sector

Pharmaceuticals

Calendar

2024-04-21 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
WUHAN HITECK BIOLOGICAL PHARMA CO.,LTD	-39.71%	400M
ELI LILLY AND COMPANY	+24.60%	672B
NOVO NORDISK A/S	+24.08%	550B
JOHNSON & JOHNSON	-5.63%	351B
MERCK & CO., INC.	+15.37%	317B
ABBVIE INC.	+7.38%	292B
ASTRAZENECA PLC	+3.26%	211B
NOVARTIS AG	+0.78%	203B
PFIZER, INC.	-9.69%	144B
AMGEN INC.	-6.63%	141B

Other Pharmaceuticals